mDR Limited AI Stock Analysis
Want to see SG:Y3D full AI Analyst Report?
mDR Limited (Y3D) AI Stock Analysis
mDR Limited
(SGX:Y3D)
The overall score of 56 reflects a company with significant operational improvements but a critical cash flow problem. The primary risk is the severe disconnect between reported profits and actual cash generation, which questions the sustainability of the turnaround and the dividend. While the valuation appears cheap and the balance sheet has improved, the bearish technical trend and poor cash conversion are major detractors, leading to a cautious, below-average rating.
mDR Limited (Y3D) vs. iShares MSCI Singapore ETF (EWS)
- Market Cap
- SGD 76.17M
- Dividend Yield
- 5.31%
- Average Volume (3M)
- 1.03M
- Price to Earnings (P/E)
- 7.0
- Beta (1Y)
- 1.46
- Revenue Growth
- 18.77%
- EPS Growth
- 5.77%
- Country
- Singapore
- Employees
- 241
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Technology Distributors
mDR Limited Business Overview & Revenue Model
Company Description
mDR Limited operates as an investment holding company, primarily involved in the distribution and retail of telecommunication products and services across Singapore and Malaysia. The company's operations are divided into four distinct segments: After...
How the Company Makes Money
null
mDR Limited Financial Statement Overview
Summary
Financial performance is mixed. The income statement shows a strong operational turnaround with record revenue and a return to net profitability, and the balance sheet has been strengthened with reduced leverage. However, these positives are severely undermined by extremely weak cash flow generation, with operating cash flow barely positive and a near-zero cash conversion ratio, indicating poor earnings quality.
Income Statement
72PositiveBalance Sheet
68PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 268.96M | 248.15M | 232.03M | 215.60M | 175.48M | 189.28M |
| Gross Profit | 49.15M | 39.15M | 40.95M | 32.56M | 27.52M | 24.93M |
| EBITDA | 19.06M | 14.29M | 12.54M | -34.67M | 15.72M | 10.37M |
| Net Income | 12.39M | -795.00K | 5.49M | -42.47M | 7.26M | 4.08M |
Balance Sheet | ||||||
| Total Assets | 324.47M | 283.53M | 223.58M | 177.68M | 234.14M | 224.31M |
| Cash, Cash Equivalents and Short-Term Investments | 25.91M | 12.90M | 24.19M | 27.56M | 25.80M | 46.34M |
| Total Debt | 98.08M | 114.37M | 53.07M | 57.08M | 66.33M | 47.77M |
| Total Liabilities | 132.81M | 143.90M | 74.68M | 80.58M | 82.42M | 66.38M |
| Stockholders Equity | 191.13M | 139.14M | 148.43M | 96.62M | 151.23M | 159.38M |
Cash Flow | ||||||
| Free Cash Flow | 1.88M | 1.41M | 11.12M | 8.14M | 4.36M | 23.42M |
| Operating Cash Flow | 2.70M | 2.05M | 11.70M | 8.73M | 4.89M | 24.43M |
| Investing Cash Flow | -72.61M | -31.80M | -32.87M | 16.35M | -28.84M | -14.39M |
| Financing Cash Flow | 77.11M | 26.58M | 20.99M | -22.94M | 11.71M | 2.65M |
mDR Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:Y3D, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 43.40 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:Y3D.
mDR Limited Peers Comparison
Overall Rating
SG:A3167Neutral
SG:E2862Neutral
SG:AWX57Neutral- SG:Y3D56Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SG:A31 | 67Neutral | SGD 434.64M | 62.88 | 32.69% | ― | 74.81% | 78.57% |
| SG:E28 | 62Neutral | SGD 895.05M | 20.49 | 7.99% | 1.49% | 1.00% | -1.32% |
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| SG:AWX | 57Neutral | SGD 2.25B | 47.89 | 8.82% | 0.54% | 14.91% | 226.44% |
| SG:Y3D | 56Neutral | SGD 81.21M | 7.03 | 7.50% | 5.31% | 18.77% | 5.77% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SG:Y3D | mDR Limited | 0.03 | -0.02 | -39.29% | |
| SG:575 | ASTI Holdings Limited | 0.07 | 0.06 | 435.71% | |
| SG:A31 | Addvalue Technologies Ltd | 0.11 | 0.07 | 138.30% | |
| SG:AWX | AEM Holdings Ltd. | 6.80 | 5.04 | 285.93% | |
| SG:BDR | Willas-Array Electronics (Holdings) Limited | 0.40 | -0.64 | -61.54% | |
| SG:E28 | Frencken Group Limited | 1.84 | 0.34 | 22.34% |
mDR Limited Corporate Events
mDR Trims CytoMed Stake With Small NASDAQ Share Sale
mDR Limited has marginally reduced its shareholding in CytoMed Therapeutics Ltd, a NASDAQ-listed company, by selling 30,000 ordinary shares in market transactions on 12 October 2026. Following the disposal, mDR’s interest in CytoMed has slipped from...
mDR Limited Steps Up Trading in Quoted Securities, Lifts Investment Exposure
mDR Limited disclosed that between 27 August and 2 October 2026, the Group acquired quoted securities worth about S$15.3 million, equal to 11.0% of its latest audited net tangible assets. Over the same period, it sold quoted securities with a histori...
mDR Limited Expands Quoted Securities Portfolio With S$7.15 Million Acquisition
mDR Limited reported that between 14 and 26 August 2026, its group acquired quoted securities worth about S$7.15 million, representing 5.1% of its latest audited net tangible assets as at 31 December 2025. Over the same period, it disposed of quoted...
mDR Limited Boosts Portfolio of Quoted Securities With New Acquisitions
mDR Limited has disclosed that it acquired quoted securities valued at approximately S$10.97 million between 6 June and 13 August 2026, representing 7.9% of its latest audited net tangible assets. Over the same period, the Group sold quoted securitie...
mDR Limited Details Deployment of Rights Issue Proceeds in Q2 2026
mDR Limited reported that no warrants were exercised under its Rights cum Warrants Issue during the second quarter of 2026, leaving the warrant-related proceeds unchanged in the period. The company confirmed that its external auditors have verified t...
mDR Updates Utilisation of Rights Issue Proceeds
mDR Limited has provided an update on the deployment of net proceeds from its earlier Rights cum Warrants Issue, from which it raised S$30.53 million after expenses and loan set-offs. The update shows that S$29.69 million had been utilised prior to t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026